Can a Routine Colonoscopy Cause Microscopic Colitis?

By Wayne Persky

RSS Feed

For decades, patients were assured that infections from colonoscopy procedures were virtually impossible, with risk estimates as low as one in a million. Over the past decade, however, studies have revealed those estimates were wildly optimistic. Simultaneously, many microscopic colitis (MC) patients have raised a question medicine has barely addressed — could the aggressive bowel preparation required before a colonoscopy trigger or contribute to MC development? The answers to both questions are more concerning and uncertain than most patients realize.

The reality behind infection risks associated with contaminated scopes:

The recognition that colonoscopy carries significant infection risk emerged primarily after multiple outbreaks involving contaminated endoscopes, particularly duodenoscopes used in specialized procedures. Investigators discovered that even when hospitals followed official cleaning protocols, bacteria could survive, hidden in microscopic crevices and biofilms within the instruments.​

A major Johns Hopkins analysis found infection rates of approximately 1.1 per 1,000 screening colonoscopies and 1.6 per 1,000 non-screening colonoscopies, with even higher rates for upper endoscopy. Some outpatient centers showed infection rates exceeding 100 times previous estimates. Other reviews estimated overall endoscopic infection rates between 0.2% and 0.37%, depending on procedure type and patient population.

These numbers represent a dramatic departure from the "one in a million" assurances patients received for years.

Colonoscopes are difficult to sterilize.

Flexible endoscopes rank among the hardest reusable medical devices to disinfect properly. They contain long narrow channels, valves, hinges, and microscopic crevices where biofilms can develop. Even tiny amounts of residual organic material can protect bacteria from disinfectants.

Studies examining supposedly "patient-ready" scopes have repeatedly found contamination in approximately 1.8 to 1.9% of colonoscopes and gastroscopes. Duodenoscope contamination rates reach 9 to 15% in many studies, with some surveillance studies finding contamination exceeding 30% depending on definitions and testing methods.

Fortunately, not all contamination leads to infection — most doesn't. However, these findings demonstrate that sterilization failures occur regularly, despite the use of rigid cleaning guidelines

Despite progress, problems remain.

Significant improvements have occurred over the past decade. Hospitals now perform more rigorous post-cleaning culturing and monitoring than previously. Manufacturers have introduced redesigned scopes with removable end caps, partially disposable components, and improved channel access, particularly for high-risk duodenoscopes. Single-use disposable endoscopes are increasingly available, eliminating cross-contamination risk entirely. Enhanced sterilization procedures, and additional high-level disinfection steps have reduced some contamination rates.​

Despite these advances, serious problems persist. Contamination still occurs regularly. Biofilms remain difficult to eradicate completely. Most scopes are reused hundreds or thousands of times, and reprocessing quality varies widely between facilities. Importantly, some outbreaks occurred even when staff correctly followed manufacturer cleaning instructions, leading many experts to conclude that reusable scope design itself is fundamentally problematic.

The improvements are real and meaningful, but the problem is far from solved. Patients undergoing colonoscopy face substantially lower infection risk than a decade ago, but that risk remains measurably higher than medicine once claimed.

The Propofol poroblem — a hidden risk for food-sensitive MC patients:

Beyond infection risks and bowel preparation concerns, MC patients face another potential problem that medical professionals rarely discuss — propofol, the sedative used during most colonoscopies, contains soybean oil and egg lecithin.​

The FDA and most anesthesia societies maintain that the refining process removes enough soy protein that soy-allergic patients face minimal risk. This conclusion, however, addresses primarily classic IgE-mediated anaphylactic soy allergy (the kind that causes immediate, life-threatening reactions). It does not adequately address the very different reactions many MC patients experience.

The critical distinction medicine misses:

The medical literature largely asks: "Does propofol trigger life-threatening anaphylaxis?" But MC patients are asking a fundamentally different question: "Can it trigger immune activation, diarrhea, inflammation, or a flare?"​

These are not the same question, and the safety studies that reassure allergists about anaphylaxis risk were never designed to detect the delayed inflammatory responses characteristic of MC

Why MC patients may react despite "purified" soy oil:

Even highly refined oils may contain trace residual proteins, oxidized lipid fragments, immune-active contaminants, or compounds capable of triggering mast cell activity in susceptible individuals. For most people, these trace amounts are irrelevant. For highly sensitive MC patients, they can be meaningful.

Additionally, experimental literature suggests propofol itself—independent of soy content—can affect cytokine signaling, mast cells, epithelial barrier function, and oxidative stress pathways. These effects appear complex, dose-dependent, and have been poorly studied in MC specifically.

The delayed reaction problem:

Most anesthesia safety studies look for immediate allergic reactions: hives, airway compromise, or hypotension occurring during or immediately after the procedure. MC patients, however, often experience diarrhea hours later, inflammatory flares days later, histamine symptoms, or mucosal immune activation—outcomes that are rarely tracked or attributed to anesthesia exposure.​

This creates a massive blind spot. Gastroenterologists typically do not systematically follow patients after colonoscopy for delayed flares, and usually attribute post-procedure diarrhea to bowel prep, stress, or transient irritation. Delayed immune reactions may be substantially underreported simply because no one is looking for them.

Why the Issue Is Difficult to Study:

During a colonoscopy procedure, patients are simultaneously exposed to bowel prep chemicals, dehydration, electrolyte shifts, mucosal irritation, microbiome disruption, sedation/anesthesia, and procedural mechanical trauma. Isolating propofol's specific contribution becomes extremely difficult.​

To answer this question properly, researchers would need studies tracking MC patients receiving propofol, monitoring symptom flares after colonoscopy, measuring delayed diarrhea and inflammatory markers, and assessing mast cell activation in food-sensitive populations. To our knowledge, those studies largely do not exist.

The safety framework's blind spot:

The FDA's position adequately addresses immediate allergic risk from highly refined soy oil in the general population. But MC patients may be experiencing delayed immune activation, mast cell responses, or inflammatory flares that current anesthesia safety frameworks were never designed to evaluate.​

The existing "safe for soy allergy" framework may not adequately address highly sensitive inflammatory bowel populations like MC patients. For patients with MC who know they react to soy, the standard medical reassurance that propofol is safe deserves skepticism based on real-world patient experience, even if formal studies haven't yet documented the problem.

Bowel prep solutions are a murkier question.

The relationship between colonoscopy bowel preparation and MC development presents a more uncertain picture. Currently, there is no definitive published evidence proving that bowel prep solutions directly cause MC.​

No large epidemiologic studies have examined this question, no reliable incidence estimates exist, and no accepted data quantify what percentage of MC cases might be triggered by bowel preparations. The honest answer is that the medical community simply doesn't know whether bowel prep causes MC.

Why the concern is biologically justified:

Despite the lack of formal proof, the concern has biological merit. Colonoscopy preparations work by creating massive osmotic shifts, rapidly flushing intestinal contents, altering the mucosal environment, disrupting gut bacteria, stressing epithelial barriers, and causing intense water secretion into the bowel. For susceptible individuals, this aggressive process could theoretically damage the mucosal barrier, activate immune responses, alter gut permeability, and potentially trigger chronic inflammation.

Why? Because every one of the mechanisms resulting from exposure to colonoscopy preparations named above, is also present during MC reactions — quite a coincidence, to say the least. Obviously, an aggressive bowel cleanse checks multiple boxes as a potential trigger.​

But to illustrate once again how we all seem to respond differently to different stimuli, epidemiological evidence shows that more than a few MC patients achieve temporary remission following a cleanout/colonoscopy procedure, although in most cases, the remission fades away after a week or two.

Is this a chicken-or-egg problem?

Research into this question faces a fundamental obstacle — most patients undergo colonoscopy because they already have diarrhea or gastrointestinal symptoms. Researchers cannot easily determine whether bowel prep triggered MC or whether the patient had early undiagnosed MC before the procedure. This creates an intractable confounding problem that makes causal studies extremely difficult.​

The one scenario researchers could potentially study (the onset of chronic diarrhea following screening colonoscopy in previously asymptomatic individuals) represents a minority of cases and would require enormous sample sizes to detect statistically, because of MC's relatively low prevalence.
And to further complicate the problem, some individuals may have asymptomatic MC, prior to the colonoscopy.

Triggering flares versus causing disease:

A more plausible and likely more common scenario is that bowel prep triggers flares rather than causing new-onset MC. Patients with existing MC, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), mast cell disorders, or impaired mucosal barriers may be particularly vulnerable to symptom flares, microbiome disruption, increased intestinal permeability, and dehydration or electrolyte stress following aggressive bowel cleansing.​

This possibility is increasingly recognized clinically even though hard data remain limited. Many gastroenterologists have observed patients whose MC was previously well-controlled experiencing prolonged flares following colonoscopy preparation, suggesting the prep's disruptive effects can overwhelm compensatory mechanisms in compromised intestinal tissue.

Are modern preparations safer?

Current bowel preparations are meaningfully improved compared to older options. Large-volume polyethylene glycol protocols, and particularly sodium phosphate preparations, which caused serious electrolyte disturbances and kidney damage in some patients, have largely been replaced by better-tolerated options.

Modern approaches increasingly use split-dose regimens that divide the preparation between the evening before and morning of the procedure, improving both tolerability and colon cleansing performance. Lower-volume preparations reduce the fluid burden patients must consume. More individualized prep strategies account for patient-specific factors like kidney function, heart disease, and existing bowel conditions. Newer guidelines emphasize safer preparation selection for high-risk patients.

Research interest is growing in gentler alternatives, specifically for patients with IBD and fragile intestinal tracts, though these remain primarily in the investigation stage.

Despite these improvements, all colonoscopy preparations remain fundamentally disruptive to intestinal function by design. They must be, because adequate colon cleansing is essential for detecting lesions and performing safe procedures. The question is whether this necessary disruption has lasting consequences in susceptible individuals.

What this means for MC patients:

For patients with established MC, who are scheduled for a colonoscopy, several practical issues should be considered. A paatient's MC diagnosis should be explicitly discussed with their gastroenterologist before the procedure, so that preparation can be individualized. Split-dose preparations may be better tolerated than single-evening preparations. Aggressive electrolyte and fluid replacement before, during, and after preparation may minimize disruption.

MC patients should consider whether the colonoscopy is truly necessary or whether symptom-based management would be appropriate, particularly if a recent colonoscopy confirming MC diagnosis has been performed. Missed diagnoses are common, but MC is virtually never mistakenly diagnosed if it doesn't exist. So if a “new” gastroenterologist insists on a repeat colonoscopy, that raises a red flag, because the procedure would be very unlikely to turn up any additional useful information. Yet many gastroenterologists facing a new patient try to talk the patient into a repeat colonoscopy, because it's typically a very profitable procedure. A repeat colonoscopy should be performed only if biopsy samples were not taken during a previous colonoscopy, or screening for polyps or cancer is needed.​

For patients without known MC undergoing a screening colonoscopy, who develop persistent diarrhea afterward, awareness that colonoscopy preparation might have triggered or unmasked intestinal inflammation is important. This doesn't mean avoiding necessary colonoscopies, but it does mean that new-onset persistent diarrhea following the procedure warrants evaluation rather than assumption that symptoms will resolve spontaneously.

The bottom line:

Infection risks from a colonoscopy procedure are real and substantially higher than medicine once claimed. Current estimates suggest approximately 1 to 4 infections per 1,000 colonoscopies in many real-world settings, with higher risks in certain facilities and patient populations. Progress through improved cleaning methods, surveillance, scope redesign, and disposable technologies has meaningfully improved safety, but contamination problems have not been eliminated. The fundamental challenge of adequately sterilizing complex reusable instruments remains.

Regarding propofol sedation, the medical community has established that life-threatening anaphylactic reactions to refined soy oil are rare. However, this safety framework does not adequately address the delayed immune activation, mast cell responses, and inflammatory flares that MC patients commonly experience. Many MC patients who react to soy in their diet, report symptom flares following a colonoscopy, yet these delayed reactions fall outside the scope of anesthesia safety monitoring. The disconnect between official reassurances and patient experience suggests that current safety assumptions may be too narrow for highly food-sensitive inflammatory bowel populations.

Regarding MC and bowel preparation, the medical community currently lacks reliable data. There is no proven causal percentage, no definitive study establishing that bowel prep solutions cause MC, and insufficient research to quantify risk. However, biologically plausible mechanisms exist, and clinical experience suggests aggressive bowel cleansing may trigger or unmask disease in susceptible individuals. Whether it causes new-onset MC, or primarily triggers flares in existing subclinical disease, remains uncertain.

The questions of whether bowel prep contributes to MC and whether propofol triggers inflammatory responses in food-sensitive patients remain inadequately studied, representing significant gaps in gastroenterology research. Given that millions of colonoscopies are performed annually, and MC is now known to have substantial prevalence, rigorous investigation of these potential relationships would be valuable. Until such research exists, patients and physicians must make decisions based on incomplete information, balancing the genuine benefits of colonoscopy for cancer screening and diagnosis against uncertain but plausible risks in susceptible individuals.
​
Progress has been made on infection control, but the contamination problem, the propofol sensitivity issue, and the bowel-prep question all deserve continued attention, research investment, and honest acknowledgment of remaining uncertainties rather than premature reassurance that risks are negligible.